Skip to content

Protagonist Therapeutics

US · PTGX #1570 by market cap Listed 2016
121.40 -2.62 -2.11%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 7.88 Expensive vs history 80th percentile
5-year average 5.29 · #441 of 514 in Biotechnology
P/E ratio 27.68 Expensive vs history 78th percentile
5-year average 16.61 · forward 45.94 · #52 of 77 in Biotechnology
P/S ratio 15.49 In line with history 35th percentile
5-year average 260.14 · forward 34.40 · #202 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Protagonist Therapeutics (PTGX) 7.92B 25.67 7.30 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value120.20 Economic moatNarrow UncertaintyHigh

Trading 1.0% above Morningstar's fair value estimate.

Fair value

Protagonist Therapeutics Inc earns a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 9% premium over our quantitative fair value estimate of $120.20 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The firm's unfavorable dividend structure undermines our quantitative valuation. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. Reflecting the firm's dividends is its forward dividend yield of 0%, which lies in the bottom 30% compared with global peers. This could imply a planned dividend cut or relatively high share price, which contributes to our view that shares are expensive.

The firm's valuation metrics are an additional cause for concern. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 12.6%, for example, lies in the bottom 10% compared with peers globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Protagonist Therapeutics discussion 0 comments

Add a comment